Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech
Published in Journal of clinical oncology (01.11.2021)
Published in Journal of clinical oncology (01.11.2021)
Get full text
Journal Article
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, John C, Harrington, Bonnie, O’Brien, Susan, Jones, Jeffrey A, Schuh, Anna, Devereux, Steve, Chaves, Jorge, Wierda, William G, Awan, Farrukh T, Brown, Jennifer R, Hillmen, Peter, Stephens, Deborah M, Ghia, Paolo, Barrientos, Jacqueline C, Pagel, John M, Woyach, Jennifer, Johnson, Dave, Huang, Jane, Wang, Xiaolin, Kaptein, Allard, Lannutti, Brian J, Covey, Todd, Fardis, Maria, McGreivy, Jesse, Hamdy, Ahmed, Rothbaum, Wayne, Izumi, Raquel, Diacovo, Thomas G, Johnson, Amy J, Furman, Richard R
Published in The New England journal of medicine (28.01.2016)
Published in The New England journal of medicine (28.01.2016)
Get full text
Journal Article
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
Wang, Michael, Rule, Simon, Zinzani, Pier Luigi, Goy, Andre, Casasnovas, Olivier, Smith, Stephen D, Damaj, Gandhi, Doorduijn, Jeanette, Lamy, Thierry, Morschhauser, Franck, Panizo, Carlos, Shah, Bijal, Davies, Andrew, Eek, Richard, Dupuis, Jehan, Jacobsen, Eric, Kater, Arnon P, Le Gouill, Steven, Oberic, Lucie, Robak, Taduesz, Covey, Todd, Dua, Richa, Hamdy, Ahmed, Huang, Xin, Izumi, Raquel, Patel, Priti, Rothbaum, Wayne, Slatter, J Greg, Jurczak, Wojciech
Published in The Lancet (British edition) (17.02.2018)
Published in The Lancet (British edition) (17.02.2018)
Get full text
Journal Article
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis
Verstovsek, Srdan, Al-Ali, Haifa Kathrin, Mascarenhas, John, Perkins, Andrew, Vannucchi, Alessandro Maria, Mohan, Sanjay R, Scott, Bart L, Woszczyk, Dariusz, Koschmieder, Steffen, García-Delgado, Regina, László, Rejtő, McGreivy, Jesse S, Rothbaum, Wayne P, Kiladjian, Jean-Jacques
Published in Future oncology (London, England) (01.12.2022)
Published in Future oncology (London, England) (01.12.2022)
Get full text
Journal Article
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma
Harrington, Bonnie K, Gardner, Heather L, Izumi, Raquel, Hamdy, Ahmed, Rothbaum, Wayne, Coombes, Kevin R, Covey, Todd, Kaptein, Allard, Gulrajani, Michael, Van Lith, Bart, Krejsa, Cecile, Coss, Christopher C, Russell, Duncan S, Zhang, Xiaoli, Urie, Bridget K, London, Cheryl A, Byrd, John C, Johnson, Amy J, Kisseberth, William C
Published in PloS one (19.07.2016)
Published in PloS one (19.07.2016)
Get full text
Journal Article
P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Gulrajani, Michael, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P1006: CHARACTERIZATION OF TL‐895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
Gulrajani, Michael, Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Byrd, John C., Ali Bhat, Seema, Awan, Farrukh, Giri, Pratyush, Ratnasingam, Sumita, Hájek, Roman, Hess, Dagmar, Alves, Daniela, Maciej Zaucha, Jan, Shen, Annalise, Bilotti, Elizabeth, Mcgreivy, Jesse, P. Rothbaum, Wayne, Ciepluch, Hanna
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P1005: EFFECT OF TL‐895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2‐V617F (JAK2VF) SIGNALING
Chary Nimmagadda, Subbaiah, Marie Budde, Paulina, Sun, Kaiyan, Covey, Todd, Krejsa, Cecile, Rothbaum, Wayne P., Bubnoff, Nikolas, Khandanpour, Cyrus
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
PB2198: TRIAL IN PROGRESS: AN OPEN‐LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL‐895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
Palandri, Francesca, Gröpper, Stefanie, Loschi, Michael, Bellesso, Marcelo, Grosicki, Sebastian, Giraldo, Pilar, Harrison, Claire, Clevenger, Tracy, Stuart, Nikki, Qamoos, Hope, Vosganian, Gregory, Rothbaum, Wayne P., Verstovsek, Srdan, Vachhani, Pankit
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P1038: TL‐895, A FIRST‐IN‐CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
Loschi, Michael, Rejto, Laszlo, Chuah, Hun, Caramella, Marianna, Hernández Rivas, Jesus, Sportoletti, Paolo, Dubruille, Viviane, Bellesso, Marcelo, Gröpper, Stefanie, Crodel, Carl, Qamoos, Hope, Socotch, Ashley, Huang, Zhuying, Wall, Sarah, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Palandri, Francesca
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
S210: AN OPEN‐LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
Mascarenhas, John, Jain, Tania, Otoukesh, Salman, Gerds, Aaron T., Lucchesi, Alessandro, Romina Sosa, Iberia, Laribi, Kamel, Mishchenko, Elena, Radinoff, Atanas, Benevolo, Giulia, Vannucchi, Alessandro M., Boyer, Francoise, Quittet, Philippe, Radsak, Markus, Machet, Antoine, Bose, Prithviraj, Huang, Zhuying, Qamoos, Hope, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Passamonti, Francesco
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
Vachhani, Pankit, Perkins, Andrew, Mascarenhas, John, Al-Ali, Haifa Kathrin, Kiladjian, Jean-Jacques, Cerquozzi, Sonia, Dybko, Jaroslaw, Delgado, Regina Garcia, Rivas, Jesus Hernández, Hebart, Holger, Huang, Zhuying, Krejsa, Cecile, Qamoos, Hope, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Vannucchi, Alessandro
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
Byrd, John C., Wierda, William G., Schuh, Anna, Devereux, Stephen, Chaves, Jorge M., Brown, Jennifer R., Hillmen, Peter, Martin, Peter, Awan, Farrukh T., Stephens, Deborah M., Ghia, Paolo, Barrientos, Jacqueline, Pagel, John M., Woyach, Jennifer A., Burke, Kathleen, Covey, Todd, Gulrajani, Michael, Hamdy, Ahmed, Izumi, Raquel, Frigault, Melanie M., Patel, Priti, Rothbaum, Wayne, Wang, Min Hui, O'Brien, Susan, Furman, Richard R.
Published in Blood (09.04.2020)
Published in Blood (09.04.2020)
Get full text
Journal Article
Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)
Nimmagadda, Subbaiah Chary, Patnana, Pradeep Kumar, Budde, Paulina Marie, Ahmed, Helal, Covey, Todd, Krejsa, Cecile, Rothbaum, Wayne, Von Bubnoff, Nikolas, Khandanpour, Cyrus
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hillmen, Peter, Qamoos, Hope, Uyei, Anne, Rothbaum, Wayne M., Jurczak, Wojciech, Thieblemont, Catherine, Byrd, John C.
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53WT, Ph+ Chronic Myeloid Leukemia
Cortes, Jorge E., Jamy, Omer Hassan, Ortí, Guillermo, Prosper, Felipe, Grosicki, Sebastian, Uyei, Anne, Rothbaum, Wayne P., Nicolini, Franck E.
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Zanubrutinib in Chronic Lymphocytic Leukemia
Byrd, John C., Rothbaum, Wayne, Liang, Yang, Gale, Robert P., Brown, Jennifer R., Cohen, Aileen, Shadman, Mazyar
Published in The New England journal of medicine (04.05.2023)
Published in The New England journal of medicine (04.05.2023)
Get full text
Journal Article
A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53 WT, Ph+ Chronic Myeloid Leukemia
Cortes, Jorge E., Jamy, Omer Hassan, Ortí, Guillermo, Prosper, Felipe, Grosicki, Sebastian, Uyei, Anne, Rothbaum, Wayne P., Nicolini, Franck E.
Published in Blood (05.11.2021)
Published in Blood (05.11.2021)
Get full text
Journal Article